For some important details about Elmiron-associated retinopathy and some other Elmiron eye side effects, we point out this excerpt from the Discussion part of this recent Clinical Ophthalmology medical journal article, ” “Pentosan Polysulfate Sodium-Associated Pigmentary Retinopathy: Risk Factors and Fundus Findings”, which was published on December 24, 2021:
Some patients with [Pentosan Polysulfate Sodium / Elmiron]-associated retinopathy may unfortunately experience difficulty with dark adaptation, reading, contrast sensitivity, and changes in mesopic microperimetry. In the current study, the [Pentosan Polysulfate Sodium / Elmiron]-associated retinopathy group was more likely to have complaints of difficulty with their visual field, reading, dark adaptation, and visual acuity….
There is currently no treatment for [Pentosan Polysulfate Sodium / Elmiron]-associated maculopathy, and the retinopathy can progress even after discontinuing [Pentosan Polysulfate Sodium / Elmiron]. In a multicenter study of 11 patients who had discontinued [Pentosan Polysulfate Sodium / Elmiron], 77% continued to experience progression, with the RPE atrophy growing at a rate of 0.32mm per year, and 9% developing worsening vision over 12 months…. [footnotes omitted]
We are handling Elmiron lawsuits for patients who have developed Elmiron-associated retinopathy, retinal pigmentary changes, or pigmentary maculopathy due to their past use of Elmiron. These Elmiron lawsuits are filed against the drug companies responsible for Elmiron. This is because — despite a growing number of Elmiron-related vision loss case reports in the medical literature over the years — it was not until June 2020 that any warning about these eye problem side effects was included in the Elmiron drug label here in the US.
It is important to know that our Elmiron lawsuits for patients who have suffered any of these Elmiron eye problem side effects are filed only against the pharmaceutical companies responsible for Elmiron — not the doctors who prescribed the Elmiron as a treatment for their bladder diseases.
Significantly, it is not necessary for the patient to have been using Elmiron regularly right up until the time when their Elmiron-related vision loss was diagnosed in order to file an Elmiron lawsuit. That is, unlike most other drug injury cases, the patient could have stopped using Elmiron months before a medical doctor was able to diagnose their Elmiron-associated retinopathy, for example.[View article in full at original source]